Aortic stenosis is the most common primary valvular lesion requiring invasive treatment in Europe and North America, affecting 2–7 % of people aged 65 years and older [ ]. Transfemoral aortic valve replacement (TAVR) has become an established treatment option for elderly patients with severe aortic stenosis across the spectrum of surgical risk [ ]. Continuous technological progress and improvements in pre-procedural planning techniques are extending the indications for TAVR towards younger age groups and those at low surgical risk. While the procedural success of TAVR has increased over time, its long-term outcomes still depend on several factors, including pre-procedural health conditions. Accurate stratification of patients who are candidates for TAVR continues to be a challenge, with the STS-PROM and EuroSCORE II currently recommended by guidelines for this purpose [ ]. There is growing attention towards identifying scores or laboratory markers capable of predicting medium and long-term outcomes, with C-reactive protein (CRP) emerging as a promising marker [ ].